BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$7.41
-0.52 (-6.56%)
Open$7.74
Previous Close$7.93
Day High$8.00
Day Low$7.27
52W High$109.35
52W Low$4.56
Volume—
Avg Volume3.97M
Market Cap9.13M
P/E Ratio—
EPS$-6.89
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+283.1% upside
Current
$7.41
$7.41
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.18M | 608.9K | 644.1K |
| Net Income | -10,119,396 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -6,833,016 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |